SecBot SecBot

KRYS drug pipeline

Krystal Biotech, Inc. · 1 rated drug
$305.23
−0.1% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePilot study (proof-of-concept, equivalent to early Phase 1/2)
Time to marketKB113 is in early-stage development with no registered Phase 2/3 trial and no defined regulatory timeline. The company is in discussions with the FDA to determine the clinical development plan. If a pivotal program is agreed upon and initiated in 2027, potential approval would likely be several years away, barring a breakthrough or accelerated pathway.

KB113 Updated Nov 2

What to watch

Watch for Krystal Biotech's announcement of FDA alignment on KB113's clinical development plan, which will define whether the program advances into a registrational trial or requires additional dose-finding studies. The small pilot (n=3) provides proof-of-concept but the regulatory path and timeline remain undefined, making KB113 a pipeline story rather than a near-term catalyst.

Bull case
  • 83.1% of assessed BCC lesions (69/83) regressed across all 3 patients, including 40 of 47 non-injected lesions, demonstrating a systemic abscopal immune response that could differentiate KB113 from local therapies.
  • All 3 biopsied lesions with >=90% regression showed histologically confirmed complete clearance, and all 22 adverse events were mild or moderate with no serious events, suggesting a favorable safety profile.
  • Gorlin syndrome patients face a lifetime burden of multiple BCCs requiring repeated surgeries; a well-tolerated intratumoral immunotherapy that shrinks both injected and distant lesions could address a significant unmet need.
Bear case
  • The entire pilot study enrolled only 3 patients, far too small to establish efficacy or safety; larger trials could fail to replicate the results.
  • KB113 is a low-dose formulation of KB707, which itself is still in Phase 1/2 testing (OPAL-1 study); any safety or manufacturing issues with KB707 could affect KB113.
  • Existing oral hedgehog-pathway inhibitors (vismodegib/Erivedge, sonidegib/Odomzo) are already approved for BCC in Gorlin syndrome, though they are poorly tolerated; KB113 must demonstrate a clear tolerability and efficacy advantage to displace them.